CD44 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathologic Features
Table 4
Adjusted odds ratio (AOR) and 95% confidence interval (CI) of clinical status and CD44 rs187115 genotypic frequencies in 123 HCC patients without smoking.
Variable
Genotypic frequencies
AA ()
AG+GG ()
OR (95% CI)
AOR (95% CI)
(%)
(%)
Clinical stage
Stage I/II
55 (74.3%)
28 (57.1%)
1.00
1.00
Stage III/IV
19 (25.7%)
21 (42.9%)
2.171 (1.006–4.687)*
2.259 (1.036–4.924)*
Tumor size
≦T2
55 (74.3%)
31 (63.3%)
1.00
1.00
>T2
19 (25.7%)
18 (36.7%)
1.681 (0.770–3.669)
1.441 (0.409–5.077)
Lymph node metastasis
No
73 (98.6%)
45 (91.8%)
1.00
1.00
Yes
1 (1.4%)
4 (8.2%)
6.489 (0.703–59.899)
6.876 (0.308–153.563)
Distant metastasis
No
72 (97.3%)
44 (89.8%)
1.00
1.00
Yes
2 (2.7%)
5 (10.2%)
4.091 (0.761–21.998)
16.533 (0.848–322.266)
The Child-Pugh grade
A
54 (73.0%)
36 (73.5%)
1.00
1.00
B or C
20 (27.0%)
13 (26.5%)
0.975 (0.431–2.204)
0.918 (0.244–3.455)
HBsAg
Negative
45 (60.8%)
29 (59.2%)
1.00
1.00
Positive
29 (39.2%)
20 (40.8%)
1.070 (0.512–2.235)
1.229 (0.293–5.160)
Anti-HCV
Negative
42 (56.8%)
25 (51.0%)
1.00
1.00
Positive
32 (43.2%)
24 (49.0%)
1.260 (0.610–2.601)
1.228 (0.342–4.410)
Liver cirrhosis
Negative
15 (20.3%)
17 (34.7%)
1.00
1.00
Positive
59 (79.7%)
32 (65.3%)
0.479 (0.211–1.083)
0.295 (0.077–1.133)
The ORs analyzed by their 95% CIs were estimated by logistic regression models. The AORs with their 95% CI were estimated by multiple logistic regression models, after controlling for age, gender, and alcohol consumption. >T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s).
*
value < 0.05 is statistically significant.